Pneumonia Vaccines for CLL
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use immunosuppressive medication within 14 days before starting the trial, except for certain allowed steroids.
What data supports the effectiveness of the treatment Pneumococcal 13-valent Conjugate Vaccine and Pneumococcal Polyvalent Vaccine for patients with chronic lymphocytic leukemia (CLL)?
Research shows that the 13-valent pneumococcal conjugate vaccine (PCV13) triggers a better immune response than the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with CLL. Although the overall immune response is low, PCV13 followed by PPSV23 is recommended to help prevent pneumococcal infections in these patients.12345
Is the pneumonia vaccine safe for people with chronic lymphocytic leukemia (CLL)?
How does the pneumococcal vaccine treatment for CLL differ from other treatments?
What is the purpose of this trial?
This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect against bacteria that cause pneumococcal disease. Giving these vaccinations as series may make a stronger immune response and prevent against pneumococcal infections in patients with chronic lymphocytic leukemia.
Research Team
Daniel Ermann, MD
Principal Investigator
Huntsman Cancer Institute/ University of Utah
Eligibility Criteria
This trial is for adults aged 18+ with chronic lymphocytic leukemia who haven't had prior CLL treatment, or those treated with venetoclax for at least a year. Participants should not have used immunosuppressants recently, except certain steroids, and mustn't have had specific pneumonia vaccines in the last five years.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive pneumococcal 20-valent conjugate vaccine on day 1 and pneumococcal polyvalent vaccine on day 60
Follow-up
Participants are monitored for immune response and safety after vaccination
Treatment Details
Interventions
- Pneumococcal 13-valent Conjugate Vaccine
- Pneumococcal Polyvalent Vaccine
Pneumococcal 13-valent Conjugate Vaccine is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Invasive pneumococcal disease
- Community-acquired pneumonia
- Invasive pneumococcal disease
- Community-acquired pneumonia
- Invasive pneumococcal disease
- Community-acquired pneumonia
- Invasive pneumococcal disease
- Community-acquired pneumonia
- Invasive pneumococcal disease
- Community-acquired pneumonia
- Invasive pneumococcal disease
- Community-acquired pneumonia
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Utah
Lead Sponsor
National Cancer Institute (NCI)
Collaborator